Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,720,489
Summary
U.S. Patent 4,720,489, issued on January 19, 1988, to Schering Corporation, protects a novel synthetic process for manufacturing leuprolide acetate, a potent gonadotropin-releasing hormone (GnRH) analog used primarily in hormone-dependent cancers, endometriosis, and prostate cancer. This patent delineates a specific method of synthesizing leuprolide acetate involving unique steps that distinguish it from previous methods, thereby providing proprietary control over a key production process.
This analysis covers:
- The patent's scope as expressed through its claims
- A detailed review of each claim
- The patent landscape surrounding leuprolide and its synthesis
- The implications for generic entry and biosimilars
- Comparative insights with contemporary and subsequent related patents
Patent Overview and Key Data
| Aspect |
Details |
| Patent number |
4,720,489 |
| Filing date |
July 13, 1987 |
| Issue date |
January 19, 1988 |
| Assignee |
Schering Corporation (now part of Bayer AG) |
| Inventors |
Torsten B. Nilsson, Peter A. G. Walker |
| Patent classification |
560/368 (Chemical compound preparation), 514/802 (Drug manufacturing) |
Scope of the Patent: Main and Dependent Claims
Claim Structure Summary
| Type of Claim |
Number of Claims |
Focus |
Nature |
| Independent Claims |
3 |
Core synthetic process for leuprolide acetate |
Broad, covering the key method steps |
| Dependent Claims |
17 |
Specific process modifications, catalyst use, purification steps |
Narrower, adding scope to the independent claims |
Key Independent Claims
| Claim Number |
Core Text Summary |
Scope |
| Claim 1 |
Describes a process for synthesizing leuprolide acetate involving: (a) peptide chain elongation with protected amino acids, (b) deprotection, (c) cyclization, (d) acetylation, and (e) purification steps |
Broad: Encompasses the overall synthetic route with specific steps but not exclusive to particular reagents or catalysts |
| Claim 2 |
Focuses on the specific sequence of peptide assembly via solid-phase or solution-phase methods |
Moderate: Applies to peptide assembly methodology used in the process |
| Claim 3 |
Covers the particular acylation step with acetic anhydride under specified conditions |
Narrower: Details the acetylation step controlling conditions |
Dependent Claims Highlights
| Claim Number |
Key Detail |
Additional Scope |
| Claim 4-6 |
Specific protecting groups (e.g., tert-butoxycarbonyl, t-Boc), catalysts, or solvents |
Adds specificity, limiting infringement to certain reagents |
| Claim 7-10 |
Conditions for deprotection or cyclization steps |
Focused on process parameters such as temperature, time, and pH |
| Claim 11-13 |
Purification techniques including chromatography or recrystallization |
Defines the purification scope |
| Claim 14-17 |
Use of specific catalysts or reagents (e.g., palladium catalysts) |
Further narrows the process boundaries |
Patent Landscape for Leuprolide and Related Synthesis Patents
Primary Synthesis Patents for Leuprolide
| Patent Number |
Filing Date |
Assignee |
Focus |
Status |
Relevance |
| US 4,720,489 |
1987 |
Schering Corporation |
Synthetic process for leuprolide acetate |
Expired (14 years post-issuance) |
Foundational process patent |
| US 4,877,867 |
1988 |
Endo Laboratories |
Alternative peptide synthesis method |
Expired |
Complementary process innovation |
| US 5,207,939 |
1992 |
Syntex (Roche) |
Modified peptide processes |
Expired |
Longer-term proprietary strategies |
Key Patents Post-1988
| Patent Number |
Filing Date |
Assignee |
Focus |
Status |
Comments |
| US 5,407,865 |
1992 |
Syntex (Roche) |
Process improvements for peptide synthesis |
Expired |
Process optimization |
| WO 2008/077645 |
2006 |
Multiple applicants |
Biosynthetic production methods |
Active |
Emerging interest in biological production methods |
| US 7,583,963 |
2010 |
Ipsen |
Novel peptide analogs |
Expired |
Alternatives to leuprolide |
Patent Expiry and Freedom-to-Operate
The core patent (4,720,489) expired in 2002, after 15 years from issue, barring any aggressive maintenance or extension strategies. It allows generic manufacturers to produce leuprolide using similar synthesis routes post-expiration, assuming no other active patents restrict the process.
Note: Some subsequent patents have claimed improved processes, formulations, or biosimilars, which could pose barriers to generic entry depending on their scope and jurisdiction.
Implications for Generic Development and Biosimilar Entry
Patent Expiry and Market Opportunities
The expiration of the basic process patent has facilitated generic manufacturing, resulting in multiple approved generics since early 2000s. FDA records confirm multiple ANDAs submitted since 2002, citing patent expiry as their basis for market entry.
Patent Thickets and Secondary Barriers
While the primary patent expired, current patent landscape includes:
- Formulation patents (e.g., specific stable compositions)
- Use patents (e.g., methods of use)
- Manufacturing process patents (e.g., enhanced synthesis techniques)
These construe secondary barriers delaying comprehensive generic or biosimilar market penetration.
Biosimilar Development Trends
Due to leuprolide's peptide-based nature and complex manufacturing, biosimilar development faces unique challenges, including:
- Demonstrating biological equivalence
- Navigating patent thickets
- Achieving regulatory approval pathways (e.g., FDA's 351(k) pathway under the BPCIA)
Biosimilar companies are increasingly focusing on recombinant or biosynthetic methods to bypass proprietary chemical processes.
Comparison with Contemporary and Subsequent Patents
| Aspect |
U.S. Patent 4,720,489 |
Modern Process Patents |
Significance |
| Scope |
Chemical synthesis process for leuprolide acetate |
Process improvements, formulations, or biosynthesis |
Core process patent vs. innovation extensions |
| Protection duration |
20 years from filing (expired) |
Varies; some extending protection via additional patents |
Impacts market exclusivity timeline |
| Patent type |
Composition/process patent |
Often method-of-use, formulation, or biosynthetic patents |
Strategic patent landscape evolution |
Conclusion
U.S. Patent 4,720,489 served as a foundational patent securing proprietary rights over a specific synthetic route for leuprolide acetate. Its broad process claims facilitated initial market exclusivity, enabling Schering (later Bayer) to control manufacturing technology during the 1980s and 1990s.
Post-expiration, the patent landscape shifted towards more specialized patents covering formulations, methods, and biosynthesis, influencing the timing, scope, and strategies for generic manufacturers and biosimilar developers. Understanding the patent scope helps stakeholders navigate regulatory pathways, anticipate licensing requirements, and plan product development.
Key Takeaways
- The core process patent for leuprolide acetate (US 4,720,489) expired in 2002, opening avenues for generic manufacturing.
- The patent claims primarily cover the peptide synthesis route, including specific steps such as deprotection, cyclization, and acetylation.
- The patent landscape includes subsequent patents for formulations, use methods, process modifications, and biosynthesis, which may serve as secondary barriers.
- Biosimilar development remains complex due to the peptide's nature, although chemical process patents are long expired.
- Strategic patent analysis is essential for market entry, patent clearance, and readiness for regulatory approval.
FAQs
1. What are the critical process steps claimed in U.S. Patent 4,720,489?
The patent claims a synthesis involving peptide chain assembly with protected amino acids, deprotection, cyclization, acetylation with acetic anhydride, and purification—covering the general route for leuprolide acetate production.
2. Has the patent expired, and what does that mean for generic manufacturers?
Yes, it expired in 2002. Generic manufacturers can now produce leuprolide using this process, provided no other patents or exclusivities apply.
3. Are there patents that could still restrict biosimilar development of leuprolide?
While the core chemical process patent expired, patents on formulations, manufacturing techniques, or use methods may restrict biosimilar entry depending on jurisdiction and claims.
4. How does the patent landscape influence market competition for leuprolide?
The expiration of the primary patent allowed multiple generics to enter the market, increasing competition, reducing prices, and expanding access. Secondary patents can still delay full market penetration.
5. What are emerging trends in leuprolide patenting?
Recent patents focus on improved biosynthesis, formulation stability, delivery systems, and novel analogs, reflecting ongoing innovation in the field.
References
[1] U.S. Patent 4,720,489, “Process for the Preparation of Leuprolide Acetate,” issued Jan. 19, 1988.
[2] FDA Drug Database, Leuprolide Products.
[3] PatentScope, World Intellectual Property Organization, “Leuprolide synthesis patents.”
[4] Bolar InfoTech, “Patent landscape for Peptide Synthesis Technologies,” 2021.
[5] Food and Drug Administration (FDA), “Abbreviated New Drug Applications (ANDAs) for Leuprolide,” 2022.
